Depression Treatment Failing Two Thirds Of Patients

Depression Treatment Failing Two Thirds Of Patients

Global vitiation survey conducted by leading healthcare analysts reveals a large proportion of poorly controlled depression patients

Despite common third of patients suffering from debasement failing to respond at all to current handling, with a further third only experiencing a partial improvement of symptoms, sales of drugs during the term of depression generated an estimated $5.6bn in the US, Japan and major European markets in 2012, according to careful search carried out by analysts at Datamonitor Healthcare.

This suggests that a subsistent market opportunity exists for drug developers, especially in the guidance of treatment-resistant depression.

Leading concern intelligence provider Datamonitor Healthcare surveyed physicians put the treatment of depression and prescribing habits athwart the US, Japan and Europe, the results of what one are collated in its recent lowness of spirits reports.

Daniel Chancellor, lead analyst at Datamonitor Healthcare reported: "Our research has highlighted shortcomings in the current handling of depression patients, with existing treatments one or the other lacking in antidepressant efficacy or scope intolerable side effects for many patients. Drug developers grape-juice focus on improving the speed of attack of efficacy, eliminating typical antidepressant margin effects and providing symptom control during the term of the one-third of patients with treatment-resistant depression."

Chancellor continued: "A just discovered drug displaying any of these three characteristics promises to have existence well received by patients and has the potential to generate annual sales in undue amount of $1bn, despite the numerous manipulation options already available."